Pharmacy Acquisition Earnouts and Script Retention
A pharmacy acquisition earnout is a provision that makes part of the purchase price depend on how the pharmacy performs after closing, often measured by how many prescriptions, or scripts, the business retains. It is one way buyers and sellers try to share the risk that patients will leave when ownership changes.
Script attrition is a real concern in pharmacy deals. Patients may follow a departing pharmacist, switch to a mail-order option or move to a competitor during the transition. An earnout attempts to price that uncertainty, but it adds complexity and can conflict with lender and program requirements. This guide explains the basics. Terms vary by deal, and nothing here is legal, tax, billing or compliance advice.
Why Script Retention Matters to Value
Much of a pharmacy’s value lies in its recurring prescriptions. If a meaningful share of patients leave after closing, the buyer may end up paying for cash flow that never materializes. Factors that can affect retention include:
- How closely patients identify with the selling pharmacist
- Whether key staff stay through the transition
- Changes in hours, services, delivery or location
- Payer network changes after the change of ownership
- Competitor activity during the transition
Our article on how a pharmacy practice is valued explains how retention risk is reflected in price more broadly.
How a Pharmacy Acquisition Earnout Works
In an earnout, the buyer pays a base price at closing and agrees to pay an additional amount later if defined targets are met. Elements to negotiate include:
- The metric: prescription counts, revenue, gross profit or another measure
- The baseline: what historical period the target is compared against
- The measurement period: how long after closing performance is measured
- The payment formula: all-or-nothing, tiered or proportional
- Exclusions: how to treat events outside either party’s control, such as payer policy changes or a major prescriber leaving
- Reporting and audit rights: how the seller can verify the results
Clear definitions help reduce disputes. Counsel should draft the provisions, and accountants can help define the metrics.
Choosing the Right Metric
Prescription counts are easy to understand but do not reflect profitability, since a script for a low-margin generic counts the same as a profitable one. Revenue can be inflated by high-cost, low-margin drugs. Gross profit may better reflect value but is more affected by the buyer’s own decisions on pricing and purchasing. Each metric has trade-offs, and the parties should agree on how buyer-controlled changes will be treated.
Lenders and Programs May Limit Earnouts
Earnouts create a contingent obligation that a lender must account for. Depending on the lender and loan program, they may:
- Restrict or prohibit earnouts in the transaction
- Require earnout payments to be subordinate to the senior loan
- Limit when and how earnout payments can be made
- Factor potential earnout payments into cash flow analysis
SBA program rules, in particular, may restrict how contingent payments to a seller can be structured in a change of ownership. Eligibility and terms depend on the business, the buyer, use of proceeds, current program rules and lender review. Our overview of SBA loans for pharmacy acquisition covers these loans more broadly. Buyers should raise any proposed earnout with their lender before finalizing the letter of intent. Every loan is subject to approval, and nothing here is a commitment to lend.
Alternatives to a Pharmacy Acquisition Earnout
When an earnout is not permitted or practical, parties sometimes use other tools to share retention risk:
- Seller notes: a deferred, fixed payment to the seller, typically subordinate to the senior lender, as explained in our article on pharmacy seller financing
- Price adjustments before closing: reflecting known risks in the base price
- Seller transition agreements: keeping the seller involved to introduce patients and prescribers
- Non-compete agreements: reviewed by counsel because enforceability varies by state
In a prescription file purchase, where retention is the entire value, payments tied to transfers are sometimes used. Our article on how to finance a pharmacy prescription file buy discusses that scenario.
Protecting Retention After Closing
Whatever structure is used, both sides benefit when patients stay. Practical steps include:
- Announcing the transition with a consistent, reassuring message
- Keeping familiar staff, hours and services where possible
- Having the seller introduce the buyer to patients and prescribers
- Confirming network participation so claims are not disrupted
- Investing in service, delivery and refill synchronization
Our guide to pharmacy patient retention strategies offers more ideas.
Tax and Accounting Considerations
Contingent payments can be treated differently from fixed purchase price for tax and accounting purposes, and the treatment may affect both the buyer and the seller. How the earnout is characterized, when payments are recognized and how they interact with any price allocation are questions for each party’s accountant before the agreement is signed.
Potential Downsides
Earnouts can lead to disagreements over how results were calculated or whether the buyer’s decisions affected performance. They may also keep the seller financially tied to a business they no longer control. Buyers should weigh whether the risk sharing is worth the added complexity and potential friction.
Final Thoughts
A pharmacy acquisition earnout can help buyers and sellers bridge differing views on script retention, but it must be carefully defined and may be limited by lenders and loan programs. Discussing the structure early with counsel, accountants and your lender can help you decide whether an earnout, a seller note or another approach best fits the deal.
US Medical Funding helps pharmacists and investors structure and finance independent pharmacy acquisitions. Learn more about our pharmacy acquisition financing and our full range of pharmacy financing options.
